290 related articles for article (PubMed ID: 17711521)
1. Histone deacetylase inhibitors preferentially augment transient transgene expression in human dermal fibroblasts.
Yasukawa K; Sawamura D; Goto M; Nakamura H; Shimizu H
Br J Dermatol; 2007 Oct; 157(4):662-9. PubMed ID: 17711521
[TBL] [Abstract][Full Text] [Related]
2. Potent stimulation of gene expression by histone deacetylase inhibitors on transiently transfected DNA.
Nan X; Hyndman L; Agbi N; Porteous DJ; Boyd AC
Biochem Biophys Res Commun; 2004 Nov; 324(1):348-54. PubMed ID: 15465025
[TBL] [Abstract][Full Text] [Related]
3. Impact of novel histone deacetylase inhibitors, CHAP31 and FR901228 (FK228), on adenovirus-mediated transgene expression.
Taura K; Yamamoto Y; Nakajima A; Hata K; Uchinami H; Yonezawa K; Hatano E; Nishino N; Yamaoka Y
J Gene Med; 2004 May; 6(5):526-36. PubMed ID: 15133763
[TBL] [Abstract][Full Text] [Related]
4. Inhibitors of histone deacetylases promote hematopoietic stem cell self-renewal.
Young JC; Wu S; Hansteen G; Du C; Sambucetti L; Remiszewski S; O'Farrell AM; Hill B; Lavau C; Murray LJ
Cytotherapy; 2004; 6(4):328-36. PubMed ID: 16146885
[TBL] [Abstract][Full Text] [Related]
5. p21Waf1/Cip1 is a common target induced by short-chain fatty acid HDAC inhibitors (valproic acid, tributyrin and sodium butyrate) in neuroblastoma cells.
Rocchi P; Tonelli R; Camerin C; Purgato S; Fronza R; Bianucci F; Guerra F; Pession A; Ferreri AM
Oncol Rep; 2005 Jun; 13(6):1139-44. PubMed ID: 15870934
[TBL] [Abstract][Full Text] [Related]
6. Anti-arthritic effects of combined treatment with histone deacetylase inhibitor and low-intensity ultrasound in the presence of microbubbles in human rheumatoid synovial cells.
Nakamura C; Matsushita I; Kosaka E; Kondo T; Kimura T
Rheumatology (Oxford); 2008 Apr; 47(4):418-24. PubMed ID: 18281366
[TBL] [Abstract][Full Text] [Related]
7. The histone deacetylase inhibitors suberoylanilide hydroxamic (Vorinostat) and valproic acid induce irreversible and MDR1-independent resistance in human colon cancer cells.
Fedier A; Dedes KJ; Imesch P; Von Bueren AO; Fink D
Int J Oncol; 2007 Sep; 31(3):633-41. PubMed ID: 17671692
[TBL] [Abstract][Full Text] [Related]
8. Histone deacetylase inhibitors up-regulate the expression of tight junction proteins.
Bordin M; D'Atri F; Guillemot L; Citi S
Mol Cancer Res; 2004 Dec; 2(12):692-701. PubMed ID: 15634758
[TBL] [Abstract][Full Text] [Related]
9. Cyclic hydroxamic-acid-containing peptide 31, a potent synthetic histone deacetylase inhibitor with antitumor activity.
Komatsu Y; Tomizaki KY; Tsukamoto M; Kato T; Nishino N; Sato S; Yamori T; Tsuruo T; Furumai R; Yoshida M; Horinouchi S; Hayashi H
Cancer Res; 2001 Jun; 61(11):4459-66. PubMed ID: 11389076
[TBL] [Abstract][Full Text] [Related]
10. Histone deacetylase inhibitor-induced cellular apoptosis involves stanniocalcin-1 activation.
Law AY; Lai KP; Lui WC; Wan HT; Wong CK
Exp Cell Res; 2008 Oct; 314(16):2975-84. PubMed ID: 18652825
[TBL] [Abstract][Full Text] [Related]
11. SULF1 inhibits tumor growth and potentiates the effects of histone deacetylase inhibitors in hepatocellular carcinoma.
Lai JP; Yu C; Moser CD; Aderca I; Han T; Garvey TD; Murphy LM; Garrity-Park MM; Shridhar V; Adjei AA; Roberts LR
Gastroenterology; 2006 Jun; 130(7):2130-44. PubMed ID: 16762634
[TBL] [Abstract][Full Text] [Related]
12. Epigenetic therapy using the histone deacetylase inhibitor for increasing therapeutic gain in oral cancer: prevention of radiation-induced oral mucositis and inhibition of chemical-induced oral carcinogenesis.
Chung YL; Lee MY; Pui NN
Carcinogenesis; 2009 Aug; 30(8):1387-97. PubMed ID: 19351790
[TBL] [Abstract][Full Text] [Related]
13. Mechanisms of HDAC inhibitor-induced thrombocytopenia.
Matsuoka H; Unami A; Fujimura T; Noto T; Takata Y; Yoshizawa K; Mori H; Aramori I; Mutoh S
Eur J Pharmacol; 2007 Oct; 571(2-3):88-96. PubMed ID: 17628529
[TBL] [Abstract][Full Text] [Related]
14. Epigenetic regulation of airway inflammation.
Adcock IM; Tsaprouni L; Bhavsar P; Ito K
Curr Opin Immunol; 2007 Dec; 19(6):694-700. PubMed ID: 17720468
[TBL] [Abstract][Full Text] [Related]
15. Effects of the histone deacetylase inhibitor trichostatin A on nuclear texture and c-jun gene expression in drug-sensitive and drug-resistant human H69 lung carcinoma cells.
El-Khoury V; Gomez D; Liautaud-Roger F; Trussardi-Régnier A; Dufer J
Cytometry A; 2004 Dec; 62(2):109-17. PubMed ID: 15517561
[TBL] [Abstract][Full Text] [Related]
16. Histone deacetylase inhibitors differentially mediate apoptosis in prostate cancer cells.
Frønsdal K; Saatcioglu F
Prostate; 2005 Feb; 62(3):299-306. PubMed ID: 15389787
[TBL] [Abstract][Full Text] [Related]
17. Histone deacetylase 7, a potential target for the antifibrotic treatment of systemic sclerosis.
Hemmatazad H; Rodrigues HM; Maurer B; Brentano F; Pileckyte M; Distler JH; Gay RE; Michel BA; Gay S; Huber LC; Distler O; Jüngel A
Arthritis Rheum; 2009 May; 60(5):1519-29. PubMed ID: 19404935
[TBL] [Abstract][Full Text] [Related]
18. Effects of histone deacetylase inhibitors on the Ah receptor gene promoter.
Garrison PM; Rogers JM; Brackney WR; Denison MS
Arch Biochem Biophys; 2000 Feb; 374(2):161-71. PubMed ID: 10666294
[TBL] [Abstract][Full Text] [Related]
19. Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors.
Khan N; Jeffers M; Kumar S; Hackett C; Boldog F; Khramtsov N; Qian X; Mills E; Berghs SC; Carey N; Finn PW; Collins LS; Tumber A; Ritchie JW; Jensen PB; Lichenstein HS; Sehested M
Biochem J; 2008 Jan; 409(2):581-9. PubMed ID: 17868033
[TBL] [Abstract][Full Text] [Related]
20. Curcumin-induced histone hypoacetylation: the role of reactive oxygen species.
Kang J; Chen J; Shi Y; Jia J; Zhang Y
Biochem Pharmacol; 2005 Apr; 69(8):1205-13. PubMed ID: 15794941
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
